Abstract:

Abstract: Objective To explore serum Cystain C (Cys C) level in chronic heart failure (CHF) patients and its relation⁃
ship with cardiac function and ventricular remodeling. Methods Patients with heart failure (n=75) and healthy adult (n=35)
were enrolled in this study. According to the NYHA classification， CHF patients is divided into NYHA Ⅱ, NYHA Ⅲ and
NYHA Ⅳ； CHF patients can also be divided into 2 groups base on their level of serum Cys C: Cys C > 0.95 mg/L is defined
as elevated serum Cys C group, serum Cys C≤ 0.95 mg/L is defined as normal serum Cys C group; According to left ventricu⁃
lar ejection fraction (LVEF), CHF patients can also be divided into 2 groups: LVEF≥ 0.50 is defined as ejection fraction re⁃
served group, LVEF < 0.50 is defined as the ejection fraction reduced group. Cys C, N terminal B-type natriuretic peptide
(NT-proBNP), serum creatinine（Scr） ,UREA and Echocardiography were analyzed in all groups and their correlation was
studied. Results Serum Cys C level in CHF patients was obviously higher than that in healthy controls, and it increased
with NYHA heart function classification; compared with normal Cys C group， Cys C elevated group presented higher NTproBNP level but lower eGFR and LVEF (P < 0.05);compared with ejection fraction reduced group, ejection fraction reserved
group demonstrated lower NT-proBNP, LVEDD, LVMI and Cys C levels (all P < 0.05); Correlation analysis revealed that
Cys C is correlated with age, NT-proBNP, LVEF, LVEDD, Scr and UREA (r=0.411, 0.658, 0.465, 0.310, 0.552, 0.486, P <
0.01). Conclusion Serum Cys C can be used to evaluate cardiac function of heart failure, and is associated with ventricular
remodeling.

Key words: heart failure, ventricular remodeling, cystatin C, cardiorenal syndrome, NT-proBNP